Genfit S.A.
GNFTF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$471.83M
Close$
$-10.65
213% downside
Current Fair Value
213% downsideOvervalued by 213% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $471.83 Million |
|---|---|
| Enterprise Value | $537.28 Million |
| Earnings per Share | $-1.73 |
| Beta | 1.14 |
| Outstanding Shares | 50,231,000 |
Return
| Return on Equity | 284.57% |
|---|---|
| Return on Assets | -91.75% |
| Return on Invested Capital | -146.36% |
Valuation & Multiples
| P/E Ratio | -4.25 |
|---|---|
| PEG | -2.62 |
| Price to Sales | 9.43 |
| Price to Book Ratio | -9.43 |
| Enterprise Value to Revenue | 5.56 |
| Enterprise Value to EBIT | -5.71 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.33 |
| Debt to Equity | -3.62 |
Revenue Sources
No data
Last Earnings Call
Report Date
September 28, 2026
EPS Estimate
$-0.18
Consensus analyst estimateRevenue Estimate
$34.83 M
Consensus analyst estimateNext Earnings Call
Expected Date
April 8, 2027
EPS Estimate
$-0.41
Consensus analyst estimateRevenue Estimate
$28.38 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Genfit
130 employees
CEO: Pascal Prigent
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in...